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Abstract
Background: Streptococcus pneumoniae is a globally important pathogen. The Gram-positive diplococcus is a
leading cause of pneumonia, otitis media, bacteremia, and meningitis, and antibiotic resistant strains have become
increasingly common over recent years.Alanine racemase is a ubiquitous enzyme among bacteria and provides the
essential cell wall precursor, D-alanine. Since it is absent in humans, this enzyme is an attractive target for the
development of drugs against S. pneumoniae and other bacterial pathogens.
Results: Here we report the crystal structure of alanine racemase from S. pneumoniae (AlrSP). Crystals diffracted to
a resolution of 2.0 Å and belong to the space group P3121 with the unit cell parameters a = b = 119.97 Å, c =
118.10 Å, a = b = 90° and g = 120°. Structural comparisons show that AlrSP shares both an overall fold and key
active site residues with other bacterial alanine racemases. The active site cavity is similar to other Gram positive
alanine racemases, featuring a restricted but conserved entryway.
Conclusions: We have solved the structure of AlrSP, an essential step towards the development of an accurate
pharmacophore model of the enzyme, and an important contribution towards our on-going alanine racemase
structure-based drug design project. We have identified three regions on the enzyme that could be targeted for
inhibitor design, the active site, the dimer interface, and the active site entryway.
Background
Despite great advances in the development of antibio-
tics, the most common cause of community-acquired
pneumonia, Streptococcus pneumoniae, is still a globally
important pathogen, especially in children and the
elderly [1]. This Gram-positive diplococcus is a leading
cause not only of pneumonia, but also otitis media, bac-
teremia, and meningitis [2,3]. In children, S. pneumoniae
is estimated to cause more than one-third of the 2 mil-
lion deaths due to acute respiratory infections [4,5]. In
the elderly, S. pneumoniae is the most common cause of
fatal community-acquired pneumonia [6,7]. In adults
from industrialized countries, pneumococcal pneumonia
accounts for at least 30% of all cases of community-
acquired pneumonia admitted to hospital, with a fatality
rate of 11% to 44% [4]. In addition, co-infection of
influenza patients with S. pneumoniae is known to
exacerbate their clinical outcome [4]: for example, 50%
or more of the flu-associated mortality in the 1918-1919
Spanish Flu epidemic is believed to have resulted from
pneumococcal superinfections [8,9], and S. pneumoniae
co-infection has been specifically correlated with the
severity of the recent H1N1 pandemic influenza [10].
The rate of antibiotic resistance in S. pneumoniae has
escalated dramatically since penicillin-resistant strains
were first detected in the 1970s [11-15]. About 40% of
pneumococcal isolates displayed multidrug-resistant
phenotypes (resistance to three or more antibiotics)
across 38 countries in 2004 [16,17]. To meet the chal-
lenge of increasing pneumococcal drug resistance it will
be important to isolate new therapeutic compounds
effective against S. pneumoniae through the identifica-
tion of new target enzymes and the development of
effective inhibitors to these targets.
The bacterial enzyme alanine racemase (Alr; E.C.
5.1.1.1) uses a covalently-bound pyridoxal 5"-phosphate
(PLP) cofactor to catalyze the racemization of L-alanine
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of the peptidoglycan layer in bacterial cell walls [18].
Microbiological evidence has consistently shown this
enzyme to be essential in bacteria [19]. One apparent
exception was found for the Mycobacterium smegmatis
enzyme, which was able tolerate an insertion in its ala-
nine racemase gene [20]. But this exception was dis-
proved with the report of an alanine racemase deletion
mutant in M. smegmatis that did not grow without D-
alanine supplementation [19]. S. pneumoniae,u n l i k e
Escherichia coli or Pseudomonas aeruginosa,c o n t a i n s
only one gene that codes for alanine racemase [21]. The
lack of alanine racemase function in eukaryotes [22]
makes this enzyme an attractive target for antimicrobial
drug development. Structural studies are crucial to
structure-based drug design [23-25], and solving the
crystal structure of alanine racemase from S. pneumo-
niae (AlrSP) is a crucial step towards designing inhibitors
of this enzyme.
To date, crystal structures of alanine racemase
enzymes from seven different bacteria have been pub-
lished: Geobacillus stearothermophilus (AlrGS) [26-31],
P. aeruginosa (DadXPA)[ 3 2 ] ,Streptomyces lavendulae
(AlrSL) [33], Mycobacterium tuberculosis (AlrMT) [34],
Bacillus anthracis (AlrBA) [35,36], E. coli (AlrEC) [37],
and Enterococcus faecalis (AlrEF) [38]. Structures of this
enzyme from a further six microorganisms have been
deposited in the PDB: Bartonella henselae (PDB ID
3KW3), Oenococcus oeni (3HUR and 3CO8), Pseudomo-
nas fluorescens (2ODO), Actinobacillus succinogenes
(3C3K), Corynebacterium glutamicum (2DY3), and Sta-
phylococcus aureus (3OO2). In all of these structures,
Alr is a homodimeric enzyme formed by a head-to-tail
association of two monomers. Each monomer is com-
posed of an N-terminal a/b barrel and an extended b-
s t r a n dd o m a i na tt h eC - t e r m i n u s .T h ea c t i v es i t ei n
each monomer is located in the centre of the a/b barrel
and contains a pyridoxal phosphate (PLP) co-factor
covalently connected to a lysine residue by an internal
aldimine bond. The catalytic mechanism is thought to
involve two bases, the same lysine, and a tyrosine con-
tributed by the opposite monomer [30,39,40]. The entry-
way to the active site and the PLP binding site consists
of residues from loops in the a/b barrel domain of one
monomer and residues from the C-terminal domain of
the other monomer, and is roughly conical, with its base
oriented toward the outside of the enzyme [34]. Struc-
tures of alanine racemase in complex with substrate
analogs [27,28,30-32] and site-directed mutagenesis of
the enzyme [31,40,41] have elucidated the reaction
mechanism of the enzyme and verified the key roles of
active site residues. Structures of alanine racemase com-
plexed with alanine phosphonate and D-cycloserine
(DCS) show that these inhibitors covalently bind to the
PLP cofactor, which explains their ability to inhibit
eukaryotic PLP-containing enzymes in a non-specific
manner [27,30,37,38].
Determining the structure of alanine racemase from a
range of bacterial species is an important step towards
its full characterization in anticipation of inhibitor
design. Here, we report the structure of AlrSP, and com-
pare it with other published alanine racemase structures.
This crystal structure will contribute useful information
towards our structure-based drug design research aimed
at the identification and development of alanine race-
mase inhibitors.
Results and discussion
Structure determination and refinement
Crystals of AlrSP suitable for X-ray diffraction were
grown as described previously [21]. Crystals diffracted to
a resolution of 2.0 Å and belong to the space group
P3121 with the unit cell parameters a = b = 119.97 Å,
c = 118.10 Å, a = b = 90° and g = 120°. The structure
of AlrSP was solved by molecular replacement using
CNS [42] and AlrGS (PDB ID 1SFT) [29] without the
PLP cofactor as a search model. Refinement was carried
out initially with CNS, then completed with TLS refine-
ment [43] in Refmac5 [44]. After structure solution and
refinement, the final model of AlrSP, validated using
PROCHECK [45] has 92.7% of residues in the most
favored regions of the Ramachandran plot, 6.9% of resi-
dues in the additionally allowed regions and 0.3% of
residues in the generously allowed regions. The struc-
ture has root-mean-square (r.m.s.) deviations from ideal-
ity for bond lengths of 0.015 Å and for angles of 1.45°.
Further data collection and refinement statistics are
presented in Table 1.
Overall structure of AlrSP
AlrSP forms a homodimer in which the two monomers
form a head-to-tail association, typical of that seen in
other alanine racemases. Each monomer has an eight-
stranded a/b barrel domain (residues 1-238) and an
extended b-strand domain (residues 239-367) (Figure
1A). The a/b barrel of one monomer is in contact with
the b-strand domain of the other monomer (Figure 1B).
Although the two monomers have very similar folds,
they are crystallographically distinct in this crystal form
(Table 1), and noncrystallographic symmetry was not
used in refinement. The r.m.s. difference between the
Ca atoms of the two monomers after superposition is
0.38 Å, and the average B-factors of monomers A and B
are 38.4 and 46.9 Å
2, respectively. As with other alanine
racemases, the AlrSP homodimer contains two active
sites, each composed of residues from the a/b barrel of
one monomer and residues from the b-strand domain
of the other. The pyridoxal phosphate (PLP) cofactor is
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and resides inside the a/b barrel domain.
As an incidental finding, the AlrSP structure contained
additional electron density within the A monomer, at the
end of helix 1 in the N-terminal a/b barrel domain. This
planar density resembled a carboxylated aromatic ring,
therefore a benzoic acid molecule, which fitted and refined
well, was modeled into this region, even though the com-
pound was not added to purification or crystallization
conditions (topology and parameters obtained from the
Hetero-compound Information Centre-Uppsala, HIC-UP
[46]). It is situated some distance away from both the
active site entryway and the dimer interface.
Structural and biochemical comparison with closely
related alanine racemases
As noted in our previous publication [21], AlrSP displays
a high level of sequence similarity with other alanine
racemases. The structure-based sequence alignment in
Figure 2 demonstrates this similarity with alanine race-
mases from other Gram-positive bacteria: AlrEF (which
has 52% sequence identity with AlrSP), AlrGS (46% iden-
tity), AlrBA (38% identity), and AlrSL (36% identity).
Regions absolutely conserved across all of these enzymes
include the characteristic PLP binding site motif near
the N-terminus (AVVKANAYGHG), the two catalytic
amino acid residues of the active center (Lys40, Tyr263’;
throughout this paper, primed numbers denote residues
from the second monomer) and the eight residues mak-
ing up the entryway to the active site (inner layer:
Tyr263’, Tyr352, Tyr282’,a n dA l a 1 6 9 ;m i d d l el a y e r :
Arg307’, Ile350, Arg288’, and Asp170).
Superposition of the Ca atoms of monomer A from
AlrSP with equivalent alanine racemase domains from
other Gram-positive bacteria confirms the overall topo-
logical similarity between these structures (Figure 3A).
There are minor conformational differences between
these alanine racemases at the N- and C-termini and
some loops in the a/b-barrel domain. AlrSP is similar in
length to AlrSL and AlrEF; whereas AlrGS and AlrBA have
15 to 19 extra residues at the C-terminus that form an
extra b-strand and helix/turn which contact the N-ter-
mini and the closest two helices of the a/b-barrel of
each structure, and do not form part of the active site.
The significance of these extra residues or lack thereof
is unknown; future mutagenesis or domain-swap experi-
ments may help to uncover their function.
Within each alanine racemase, the C- and N-terminal
domains of each monomer are structurally distinct, and
the hinge angle varies between the different enzymes
[32,36], thereby preventing the optimal superposition of
whole monomers. Overlaying the Ca atoms of AlrSP and
alanine racemase structures from other Gram-positive
bacteria results in average r.m.s. differences of 1.16-1.57
Å (Table 2), but when the N-terminal and C-terminal
domains from AlrSP are superimposed separately, the C-
terminal domain is shown to be more conserved (aver-
age r.m.s. differences of 0.49-1.24 Å), than the N-term-
inal domain (r.m.s. of 1.30-1.92 Å). Domain boundaries
and residues used in these superpositions are listed in
Table 3. The subset of residues found in the active site
of AlrSP superpose very well with the equivalent residues
of the other structures (r.m.s. of 0.36-0.67 Å). C-termini
Table 1 Data collection and structure refinement
statistics
Data collection
Unit cell parameters a = 119.97 Å, b = 119.97 Å,
c = 118.10 Å
a = 90°, b = 90°, g = 120°
Space group P3121
l (Å) 1.5418
Mosaicity 0.48
Observations 475265
Unique reflections 66748
R-merge
a (%) 8.3 (68.2)
Completeness (%) 99.6 (95.4)
<I/s> 21.3 (1.7)
Refinement statistics
Resolution (Å) 23.03 - 2.00 (2.05 - 2.00)
Reflections 63336 (4412)
Total atoms 6161
R-factor
b (%) 16.8 (32.2)
Rfree (%) 20.0 (35.5)
Average B-factors (Å
2)
Wilson B-factor 33.2
All atoms 42.7
Main chain atoms 41.8
Side chain atoms and waters 43.6
Waters 44.5
R.m.s. deviations
Bond lengths (Å) 0.015
Bond angles (deg) 1.45
No. of residues 734, 100%
No. of protein atoms 5615
No. of PLP atoms 30
No. of benzoic acid atoms No. of
water molecules
9 507
Residues in the Ramachandran plot
Most favored regions 588, 92.7%
Additionally allowed regions 44, 6.9%
Generously allowed regions 2, 0.3%
Disallowed regions 0, 0%
a R-merge = Σ|Iobs-Iavg|/Σ|Iavg|
b R-factor = Σ|Fobs-Fcalc|/Σ|Fobs|
Values in parenthesis are for the highest resolution shell.
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between AlrSP and AlrGS, and also between AlrBA and
AlrEF. This structural similarity explains why AlrGS was
such a successful molecular replacement model. Varia-
bility in the N-terminal domain is further illustrated by
superposition of the N-terminal domains of AlrSP and
its closest available homolog, AlrEF, which reveals signif-
icant deviations in Ca positions (≥1.8 Å) for five
regions: residues 27-29, residues 53-58, residues 109-
122, residues 150-156, and residues 192-196 (Figure 3B).
T h es e q u e n c ei nt h e s er e g i o n si sn o th i g h l yc o n s e r v e d
and they lie far from the active site. Superposition of the
C-terminal domains from these structures shows no
region with Ca differences greater than 1.7 Å. Overall,
alanine racemase structures seem to tolerate significant
alterations in the backbone of the a/b-barrel and b-
domain and still retain almost identical active site resi-
due locations.
The kinetic properties for AlrSP [21] are within the
range of those previously observed for other bacterial
alanine racemases (Table 4). The KM for L-alanine is 1.9
mM and Vmax for the racemization of L- to D-alanine is
84.8 U/mg, where one unit is defined as the amount of
enzyme that catalyzes racemization of 1 μmol of sub-
strate per minute. In the other direction, the KM for D-
alanine is 2.1 mM and Vmax for the racemization of L-
to D-alanine is 87.0 U/mg. However, the Vmax for the S.
pneumoniae enzyme is more than one order of magni-
tude lower than that reported for the G. stearothermo-
philus and E. faecalis enzymes, even though the active
site of AlrSP has high sequence and structural similari-
ties with these alanine racemases. Differences of up to
three orders of magnitude have been reported in this
family despite very similar active sites.
Hinge angle
The hinge angle of the A monomer of AlrSP,f o r m e db y
the Ca atoms of residues 99, 38 and 270 in the N-term-
inal a/b barrel domain and the C-terminal b-strand
domain, is 132.3°. This is well within the range of hinge
angles found between corresponding residues in the
other Gram-positive alanine racemase structures (127.6°
for AlrBA, 129.4° for AlrGS, 131.6° for AlrEF, and 138.2°
for AlrSL). The difference in the degree of tilt between
the C-terminal domains for the five structures can be
seen in Figure 3A. Hydrogen bonding between the C-
Figure 1 Structure of alanine racemase from S. pneumoniae. (A) Ribbon diagram of the alanine racemase monomer with b-sheets colored
green and a-helices colored gold. (B) Ribbon diagram of the alanine racemase dimer where one monomer is colored blue and the opposite
monomer red. The N’-pyridoxyl-lysine-5’-monophosphate or LLP residue (PLP cofactor covalently bound to lysine; black or grey spheres) resides
in the a/b barrel domain of the active site. The active site is composed of residues from the a/b barrel domain of one monomer and residues
from the b-strand domain of the other monomer.
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posed by LeMagueres et al. to account for the distinct
domain orientations of AlrMT and DadXPA [34]. Alanine
racemase structures with extra residues at the N- and
C-terminal tails, such as AlrGS and AlrBA,o f t e nf o r m
these hydrogen bonds, which are associated with smaller
hinge angles (127.6° for AlrBA, 129.4° for AlrGS)[36].
Although the hinge angle clearly varies from species to
species for this enzyme, the active sites superpose very
well. Further, there is no correlation between hinge
angle and Vmax (data not shown). On the other hand,
there is some correlation between alanine racemase
activity and bacterial doubling time. For example, the
enzyme from the slow growing M. tuberculosis is very
slow compared to the same enzyme from the rapid
growing M. smegmatis species. It has previously been
noted that only the dimeric form of the enzyme is active
[47] and that many of the alanine racemase enzymes
with the strongest monomer-dimer association have
been found to be the most active [48]. A recent report
has appeared looking at how enzyme activity in different
alanine racemases relates to self-association affinity and
this report confirms this assertion [49].
Active site
The geometry and identities of the active site residues
of AlrSP (Figure 4A) are very similar to that of other ala-
nine racemases (Figure 4B). The main components of the
AlrSP active site include the PLP cofactor covalently
bound to Lys40 (forming an N’-pyridoxyl-lysine-5’-mono-
phosphate or LLP residue), the catalytic base residue
Tyr263’ which lies at the beginning of helix 11 in the
b-strand domain (contributed by the opposite monomer
to that providing Lys40), and a hydrogen-bonded network
Figure 2 Structure-based sequence alignment of the five solved alanine racemase structures from Gram-positive bacteria. Structures
are from S. pneumoniae, G. stearothermophilus [29], E. faecalis [38], B. anthracis [36] and S. lavendulae [33]. The black box encloses the conserved
PLP binding site, the asterisks (*) mark the PLP-bound Lys residue and the catalytic Tyr residue, the diamond (♦) marks the location of the
carbamylated Lys residue, and the residues constituting the entryway to the active site are marked with either I (inner layer) or M (middle layer).
Residues that form intermonomer interfaces are highlighted in light green. The purple shading is proportional to the degree of sequence
identity across the alignment.
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of alanine racemases proposed elsewhere [29-31,50],
AlrSP operates by a two-base mechanism where the a-
hydrogen of either D-alanine or L-alanine is abstracted
and added by a different catalytic residue. Therefore, in
the D- to L- direction, the reaction occurs with D-alanine
binding to produce an external aldmine between PLP and
D-alanine. Lys40 then abstracts the a-hydrogen to pro-
duce a carbanonic quinonoid intermediate. Next, Tyr263’
adds a proton to the Ca of the intermediate from the
opposite side to produce an external aldimine between
PLP and what is now L-alanine. Subsequent transaldimi-
nation liberates L-alanine and regenerates the LLP form
of the enzyme.
In the LLP moiety, the C4” atom of the PLP cofactor
is linked to the NZ of Lys40 by a double bond in the
trans- configuration, forming an internal aldimine as in
other alanine racemase structures [29,31-33]. The PLP
cofactor is further stabilized by hydrogen bonds with
the side chains of six residues (Tyr44, Arg136, His165,
Ser203, Arg218 and Tyr352) and main chains of three
residues (Ser203, Gly220, Asp221; Figure 4A). The
hydrogen-bonded network also includes residues His199
and Tyr263”, and was first described in AlrGS [29]. All
of these residues are strictly conserved across the Gram-
positive structures, except for Asp221, which is replaced
by an Ile in AlrBA and AlrGS,aV a li nA l r EF,a n daL e u
in AlrSL [29,33].
We observed electron density consistent with a carba-
mylated lysine at the NZ terminus of Lys129, as seen in
most other alanine racemase structures. Lys129 refined
well as a carbamylated residue in this structure and is
hydrogen bonded to the neighboring arginine residue.
Shaw et al. [29] noted that this lysine residue is highly
conserved, and later studies suggested that it helps to
position the nearby arginine residue (Arg136 in AlrSP)
which interacts with the substrate’s carboxylate group
through hydrogen-bonding [28,32]. Arg136 is further
positioned in AlrSP by a hydrogen bond to Ser309.
Sequences of alanine racemases that contain a lysine in
position 129 almost always have an accompanying serine
or cysteine residue in the equivalent of position 309
[36]. Recently, the AlrBA structure was found to contain
an aspargine residue bound to a chloride ion at the
equivalent position of Lys129, which appears to play the
same role as the carbamylated Lys of positioning
the active site arginine [36]. An alignment of alanine
racemase sequences by Couñago et al. revealed that the
presence of an aspargine residue can occur at the
equivalent position of Lys129 in AlrSP and is likely to be
indicative of an internal chloride within the active site
in the place of a carbamylated lysine. Notably this
change from Lys to Ser appears to always be accompa-
nied by a threonine at the equivalent position of Ser309,
even though the threonine does not directly interact
with the chloride ion.
The environments on either side of the pyridine ring
of PLP are quite different, as reported previously for
AlrGS [29,33]. The side of the PLP that faces the dimer
interface is polar in character, with many hydrophilic
amino acid residues (including carbamylated Lys129,
Arg136, His165 and Arg218), several water molecules
and the hydrogen-bond network. The nonpolar side of
PLP, in contact with the a/b barrel, contains several
hydrophobic residues (Val38, Leu83, Leu85 and
Phe163), no charged residues and no water molecules.
As observed in several other alanine racemase struc-
tures [29,32,34,36], we identified extra density in the
Figure 3 Superposition of alanine racemase monomers from
Gram-positive bacteria. (A) Ca atom traces of alanine racemases
from G. stearothermophilus (yellow) [29], E. faecalis (green) [38], B.
anthracis (blue) [36], S. lavendulae (red) [33], and S. pneumoniae
(pink). The superposed N-terminal a/b barrel domains are oriented
on the bottom of the picture and the C-terminal b-strand domains
on the top. Spheres represent the three structurally equivalent
residues used to measure the hinge angle in each structure. The
double-headed arrow indicates the variation between hinge angles.
The PLP-bound Lys residue from AlrSP is shown in black. (B)
Superposed ribbon representations of the N-terminal domains from
E. faecalis (green) [38] and S. pneumoniae (pink), with the most
divergent regions colored orange.
Table 2 Average r.m.s. differences (Å) between the Ca
atoms of AlrSP and alanine racemase structures from
other Gram-positive bacteria
PDB
ID
Whole
monomer
N-
terminus
C-
terminus
Active
site
AlrGS 1SFT 1.23 (46%) 1.30 (41%) 0.57 (56%) 0.36 (66%)
AlrSL 1VFH 1.57 (38%) 1.92 (34%) 1.24 (41%) 0.67 (46%)
AlrBA 3HA1 1.29 (45%) 1.59 (41%) 0.49 (53%) 0.38 (65%)
AlrEF 3E5P 1.16 (53%) 1.48 (52%) 0.54 (56%) 0.46 (71%)
Numbers in parenthesis denote sequence identity with AlrSP, (%sequence
identity = Nidentity/Naligned).
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4C). The position of this density corresponds to that of
the acetate modeled in AlrGS. In other structures, this
location has been reported to contain propionate, ala-
nine phosphonate, and a putative substrate molecule in
DadXPA [28-30,38]. Water molecules in the same loca-
tion are found in the AlrMT and AlrSL structures. After
unsuccessfully attempting to model a variety of small
molecules into the extra density, including acetate, we
left this region of the model empty.
Active site entryway
T h ee n t r y w a yt ot h ea c t i v es i t ei nA l r SP comprises the
a/b barrel domain of one monomer and residues from
the C-terminal domain of the other monomer, and is
a b o u t1 3Åf r o mt h ea c t i v es i t eC 4 ” atom of PLP. The
entryway has a funnel-like shape, with its widest end
towards the outside of the enzyme, narrowing as it
approaches the PLP. The highly conserved residues
comprising the entryway are distributed in layers begin-
ning at the PLP site (Figures 6A and 6B): charged near
the entrance, and mainly hydrophobic near the active
site [33,34]. Mutagenesis has shown that these hydro-
phobic residues have an important role in controlling
the substrate specificity of alanine racemase [51]. In
AlrSP, the inner layer is made up of residues Tyr263’,
Tyr352, Tyr282’,a n dA l a 1 6 9 .R e s i d u e sA r g 3 0 7 ’, Ile350,
Arg288’, and Asp170 make up the middle layer. The
residues composing the middle and the inner layers are
strictly conserved between AlrSP,A l r EF,A l r BA,A l r GS,
and AlrSL. An outer layer exists comprised of Thr345,
Glu171, Val232 and Gly264’, but these residues, which
are able to interact with solvent directly, are not well
conserved.
The AlrSP active site entryway includes the conserved
pair of acidic residues Asp170 and Glu171. The equiva-
lent residues in E. coli, Asp164 and Glu165, have been
posited to play a role in substrate orientation [37].
Although the active sites of alanine racemases in general
are moderate in size, it is difficult for inhibitors to
access because of a constriction in the entryway corridor
[34]. The smallest constriction in the entryway corridor
of AlrSP is between Tyr263’ and Tyr352 of the inner
layer (Figure 6A), which provide an opening width of
Table 4 Kinetic parameters for the racemization of L- to D- and D- to L-alanine by alanine racemases from Gram-
positive bacteria
D to L direction L to D direction
Enzyme [ref] Km(mM) Vmax(U/mg)
a kcat(min
-1)K m(mM) Vmax(U/mg)
a kcat(min
-1)
AlrSP [21] 2.1
b 87.0
b NR 1.9
b 84.8
b NR
AlrGS [76] 2.7
c 1400
c NR 4.3
c 2550
c NR
AlrSL [77] 0.4
c NR 3800
c 0.4
c NR 3300
c
AlrBA [36] 2.8
b 101
b NR NR NR NR
AlrEF [78] 2.2
c 1210
c ~2340
c 7.8
c 3570
c ~2340
c
aOne unit is defined as the amount of enzyme that catalyzes racemization of 1 μmol of substrate per minute.
bAt 23°C.
cAt 37°C. NR: not reported.
Table 3 Residues used in r.m.s. calculations
AlrEF AlrSP AlrGS AlrBA AlrSL
N-terminus monomer A 2-243 1-239 2-241 4-245 3-246
C-terminus monomer A 244-371 240-367 242-388 246-389 247-378
Active site monomer A 38-44 38-44 37-43 39-45 36-42
62-66 61-65 61-65 63-67 60-64
83-87 82-86 82-86 84-88 81-85
100-104 101-105 101-105 103-107 100-104
128-141 125-138 125-138 127-140 125-138
164-172 160-168 161-169 163-171 163-171
201-208 197-204 198-205 203-210 203-210
219-226 215-222 216-223 221-228 221-228
353-360 349-356 351-358 356-363 358-365
monomer B 265-268 261-264 263-266 268-271 268-271
311-316 307-312 309-314 314-319 315-320
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through (the distance between the closest atoms of
these two side chains with the van der Waals radius for
each atom subtracted). As a result, the substrate entry-
way itself has been proposed as an alternative target for
inhibitor development [32,34]. Wang et al. [52] have
proposed this idea previously for another enzyme, his-
tone deacetylase-like protein.
Dimer interface
Dimerization is essential for the catalytic activity of ala-
nine racemase [47]. Both monomers contribute to the
overall composition of the active site, the alanine entry-
way, and the binding pocket. Within the AlrSP dimer
interface there are 33 hydrogen bonds and 10 salt bridges
(Table 5). There are no disulfide or covalent bonds across
the interface. 91 residues from each monomer are
involved in intermonomer interactions. The buried sur-
face areas of the A and B monomers are 3035 and 3020
Å
2, respectively; both values are 19% of the total surface
area of each monomer. The interface surface area is simi-
lar to that seen in the closely related AlrEF and AlrGS
(Table 5). 30% of the interface residues in AlrSP are polar,
47% are non-polar, and 22% are charged.
Disruption of the dimer interface could be used to
inhibit alanine racemase activity, and has been success-
fully used on drug targets in HIV and HCV [53-55], and
on caspases [56]. Inspection of the residues that partici-
pate in the dimer interface of AlrSP on a structure-based
sequence alignment (Figure 2) makes it apparent that
that many of these residues are highly conserved, and
also participate in substrate guidance (such as middle
and inner entryway residues Tyr282’, Tyr352, Arg307’,
Ile350, Arg288’, Asp170) or catalysis (e.g. Lys40,
Tyr263’).
Pentagonal water molecules in the active site
A cluster of hydrogen-bonded water molecules forms an
ordered pentagonal ring and some adjacent partial rings
in the active site entryways of both monomers of AlrSP
(Figure 7). The pentagonal ring waters are located adja-
cent to the substrate binding site and between residues
Tyr263” and Tyr282”. They are positioned at the inter-
face of monomer A and B and appear to be involved in
the dimer interface, making direct or indirect hydrogen
bonds with interface residues (Asp170, Tyr263’,T y r 2 8 2 ’,
Tyr288’, Arg307’, Tyr352). The distance between the
water oxygen atoms that form each side of the pentagon
is about 2.7 Å. The pentagonal ring is hydrogen-bonded
directly to the protein at five atoms (Tyr282’ OH,
Arg307’ NH1, and Arg288’ NH2 and NE from the entry-
way inner and middle layers, and Val308’ O) and makes
hydrogen bonds with other waters both deeper in the
active site and at the outer region of the entryway.
Figure 4 Active site of alanine racemase from S. pneumoniae.
(A) Electron density 2Fo-Fc map of the active site contoured at 1.5s,
excluding solvent. Residues from the first monomer are colored
pink, residues from the second monomer are blue and are denoted
with primed numbers. The PLP-bound Lys residue (LLP) is grey. (B)
Superposition of the active site residues from Gram-positive alanine
racemase structures with AlrSP; only S. pneumoniae residues are
labeled. Residues pictured are from G. stearothermophilus (yellow)
[29], E. faecalis (green) [38], B. anthracis (blue) [36], S. lavendulae (red)
[33], and S. pneumoniae (pink). The chloride ion from the B.
anthracis structure is depicted as a blue sphere. (C) Unmodeled
electron density (green) found in the active site. 2Fo-Fc (light blue)
and Fo-Fc (green and red) maps are contoured at 1.5 and 3.0 s,
respectively. Residues are colored and labeled as described for
Figure 4A.
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Page 8 of 15Figure 6 Molecular surface representations of the entryway to the active site of alanine racemase from S. pneumoniae. (A) The surface
of three layers of entryway residues: residues comprising the inner layer are pink (here, the constricting Tyr352 and Tyr263’ residues can be
seen), the middle layer residues are orange, and the outer layer residues are blue. The PLP cofactor is colored green. Primed numbers denote
residues from the second monomer. (B) Surface of the entryway colored by electrostatic potential (same view as in A).
Figure 5 Schematic diagram of polar interactions around PLP in the active site of alanine racemase from S. pneumoniae. For clarity,
interactions with water molecules have not been included. Primed numbers denote residues from the second monomer. This figure was drawn
after LeMagueres et al. [32].
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Page 9 of 15Figure 7 Pentagonal ring waters near the substrate binding site in alanine racemase from S. pneumoniae. The electron density 2Fo-Fc
map is contoured at 0.8s. Residues are shown as sticks, red spheres represent water molecules, and dashed yellow lines represent hydrogen
bonds. Residues from the first monomer are colored pink, residues from the second monomer are blue and are denoted with primed numbers.
The PLP-bound Lys residue (LLP) is grey. For simplicity, only some of the residues are shown.
Table 5 Intermonomer interactions for alanine racemases from Gram-positive bacteria calculated using PISA [69] and
PROTORP [70]
Buried surface area (Å
2) H-bonds Salt link # residues % interface residues
Monomer A Monomer B A B polar non-polar charged
AlrSP 3035 3020 33 10 91 91 30 47 22
AlrGS 3058 3109 43 17 89 88 27 43 30
AlrSL 2800 2799 26 6 87 87 39 43 18
AlrBA 3529 3529 45 10 93 95 28 44 27
AlrEF 2936 2936 38 12 86 86 32 41 28
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Page 10 of 15The hydrogen bond network we have identified could
be facilitating substrate movement or proton transfer
into the active site. Analysis of conserved water sites in
AlrGS has been reported previously and the authors pos-
tulated that these sites could be involved in proton
transfer or solvent shift into the active site [57]. In the
high resolution structure of the protein crambin, Teeter
reported pentagonal rings of water molecules which
were felt to have a role in stabilizing protein structure
or in catalysis [58]. Pentagonal ring waters have not yet
been reported for other alanine racemases, but depend-
ing on which monomer is observed, the AlrBA and AlrGS
structures have 3 to 4 of the 5 pentagonal waters pre-
sent in AlrSP, the AlrSL structure has 2 of the 5 pentago-
nal waters, and the AlrEF structure does not have any
pentagonal ring waters, although this could be due to
limits in structural resolution.
Alanine racemase as a target for drug design
In this section we review some of the challenges
encountered in developing inhibitors for alanine race-
mases as a family and we explain the contribution of
the S. pneumoniae structure to this process. Finally we
offer our assessment of the most useful approaches to
alanine racemase inhibitor development.
Challenges involved in designing inhibitors for alanine
racemase are easy to identify. To begin with, there have
been few reports to date of alanine racemase inhibitors
with any true specificity. Incorporating features of the
active site in drug design has been challenging because
the structure of the active site is thought to have limited
accessibility. Further, several inhibitors have been found
to cross react with human enzymes that contain PLP.
Even so, our analysis of alanine racemase structures has
allowed us to identify key features that could be incor-
porated into the inhibitor development process. Since
these key features are also present in the S. pneumoniae
enzyme structure, it confirms that these features are not
artifacts or incidental findings but conserved features
that can be targeted in the development of a class of
inhibitors specific to bacterial alanine racemases. There-
fore the structure of the S. pneumoniae enzyme is valu-
able to racemase drug design efforts.
In addition, one new feature relevant to the traditional
drug design approach of blocking the active site that we
report here for AlrSP is the pentagonal water network
within the active site. Several of these waters are con-
served in other alanine racemase species. That being the
case, the conserved waters could be incorporated within
an in silico pharmacophore as a polar site capable of
receiving or donating a hydrogen bond depending on
its protonation state. Unfortunately, to date testing of
compounds identified from in silico screening has not
resulted in the identification of strong inhibitors.
The earliest drug development work on alanine race-
mase was carried out in the absence of a crystal struc-
ture and resulted in the development of a cycloserine, a
small, covalent inhibitor of alanine racemase and other
PLP-containing enzymes [59] that lacks any specific
interactions with elements in the active site. More
recent in silico drug design work carried out using the
structure of alanine racemase has defined a pharmaco-
p h o r es i t u a t e dw i t h i nt h ea c t i v es i t en e a rt h ea l a n i n e
racemase acetate binding site, a site reported consis-
tently within alanine racemase structures [60]. However,
analysis of the narrow entryway to the active site PLP
suggests that access to the proposed interior binding
pockets of the enzyme is likely to be limited, especially
for larger compounds [32,34]. To be an effective drug tar-
get it is important the active site be accessible, therefore
standard structure-aided inhibitor design approaches are
limited for alanine racemase.
Since, as illustrated by the AlrSP structure, entryway to
the interior binding pocket of alanine racemase is very
tight, the drug design problem for alanine racemase
resembles a “ship in a bottle” (SIAB) dilemma. Once
inside the interior pocket, the compounds proposed to
b i n dt ot h ea c t i v es i t ew o u l df i tw e l lb u tt h e s ec o m -
pounds may only make it to the interior with difficulty
[32,34,36]. This view is of course an oversimplification,
as the entryway is likely to ‘breathe’ and adjust, and
there is a monomer-dimer equilibrium for alanine race-
mase that would affect the geometry and accessibility of
internal active site cavities. However, the restricted
access and size of the alanine racemase active site is one
reason it has not been targeted by major pharmaceutical
companies in the recent past (Bussiere, Dirk; personal
communication).
If a drug design project involving an enzyme with a
SIAB active site is to be successful, there are four
obvious approaches to inhibitor development: high
throughput screening (HTS), blocking the opening,
interfering with active site assembly, or developing
drugs that enter in one shape and adopt a new confor-
mation after binding, thus trapping them in the active
site.
HTS would bypass any of the complexities associated
with active site access and would provide a set of com-
pounds that inhibit the enzyme by any and all means, to
be deconvoluted later. Given that the active site features
we describe for the S. pneumoniae enzyme are highly
conserved in the bacterial structures reported to date,
the alanine racemase inhibitors identified by HTS would
likely be broad-spectrum in their action. But a broad
spectrum of activity should not be viewed in a negative
light, as almost all major classes of antibiotics developed
to date are broad spectrum. This includes beta-lactams
like penicillin and cephalosporins, fluoroquinolones,
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Page 11 of 15tetracyclines, even macrolides. In fact the only specificity
among anti-bacterial classes currently in use would be
that some target preferentially Gram-positives, Gram-
negatives, mycobacteria or anaerobes.
Blocking the opening would involve the design of
compounds that interact with residues in the entryway
and that extend toward the PLP moiety, but that might
not reach the interior binding pocket. In our previous
work on the alanine racemase from P. aeruginosa,
M. tuberculosis and B. anthracis, we described a highly
conserved and layered entryway to the active site that
contains both hydrophobic and polar features. The
hydrophobic regions are bound by three tyrosines and
an alanine in the inner layer of entryway, while the
polar areas include two arginines and one aspartate
located in the middle layer. These highly conserved fea-
tures are present in the S. pneumoniae structure and all
alanine racemase structures reported to date. An entry-
way of this type has not been described in human
PLP-containing enzymes. For example, human serine
racemase, which like alanine racemase reacts with
D-cycloserine, belongs to the Fold type II family of PLP-
containing enzymes and would be not be expected to
cross-react with any specific alanine racemase inhibitors
[61]. The alanine racemase topology is termed Fold type
III and is unique among PLP-containing enzymes. It
seems likely, therefore, that designing inhibitors that
interact with conserved motifs found in the entryway
could represent a potential source of specificity in the
drug design process.
Interfering with active site assembly would, in the case
of alanine racemase, require compounds that inhibit
dimer formation, none of which have been reported for
alanine racemase to date. However, dimer inhibitors
have been reported in other systems such as HIV pro-
tease [53-55]. Finally, a compound that could enter the
active site of alanine racemase then undergo a confor-
mational switch rendering the enzyme inactive would
make an effective inhibitor, but this type of inhibitor has
not yet been reported for this class of enzyme.
Conclusions
Alanine racemase is a promising target for antibacterial
drugs because it is both essential in bacteria and absent in
humans. We report the high-resolution crystal structure
of alanine racemase from S. pneumoniae.O v e r a l l ,t h e
structure shares the conserved active site and topology
found across all alanine racemases. Known alanine race-
mase inhibitors such as D-cycloserine, alanine phospho-
nate, and other substrate analogues are not specific, acting
on other PLP-containing enzymes such as transaminases,
also found in humans [59,62]. In order to be clinically rele-
vant, new inhibitors of alanine racemase with more specifi-
city need to be developed. This structure is an essential
starting point for the design of more specific inhibitors of
alanine racemase in S. pneumoniae. Our investigations
have identified three potential areas in the AlrSP structure
that could be targeted in a structure-based inhibitor
design: the active site, the residues forming the dimer
interface, and the active site entryway in particular, since
designing a ‘plug’ to fit the funnel shape of this feature is
intuitively attractive.
Methods
Protein expression, purification and crystallization
The expression, purification and crystallization of AlrSP
have been described previously [21]. Briefly, the gene
encoding AlrSP was cloned into pET17 (Novagen) and
the resulting vector transformed into E. coli BL21 (DE3)
pLysS cells (Novagen). Overexpression of AlrSP was
induced in a culture of these cells, which were then
lysed to extract the protein. The recombinant AlrSP was
purified using ammonium sulfate precipitation, anion-
exchange chromatography, hydrophobic interaction
chromatography, and finally, size-exclusion chromato-
graphy. Crystals of AlrSP were grown at 4°C in 1.2 M
Na Citrate, 0.1 M MES, pH 7.2, and 10% glycerol (pro-
tein concentration 23 mg/ml, drop size 4 μl+4μl)
using the sitting drop vapor diffusion method, then
flash-frozen in liquid N2 for data collection. No addi-
tional cryoprotectant was required.
Data collection and processing
Diffraction data were collected to 2.0 Å resolution at
100 K using a Rigaku FR-E generator and an HTC
detector at 45 kV and 45 mA with Cu Ka radiation at
R i g a k uM S C( T h eW o o d l a n d s ,T X ) .T h ec r y s t a l s
belonged to the space group P3121 with the unit cell
parameters a = b = 119.97 Å, c = 118.10 Å, a = b = 90°
and g =1 2 0 ° .T h ed a t aw e r ep r o c e s s e da n dm e r g e d
using the HKL package version 1.96.6 [63]. Data collec-
tion and processing statistics are listed in Table 1.
Structure determination and refinement
The structure of AlrSP was solved by molecular replace-
ment using CNS version 1.1 [42]. AlrGS (PDB ID 1SFT)
[29] without the PLP cofactor was used as a search
model, and two monomers per asymmetric unit were
assumed, as suggested by a Matthews coefficient [64] of
3.0 with a solvent content of 59.0%. Cross-rotation and
translation searches were completed and the best solu-
tion was used as an initial model for model building.
After rigid body refinement in CNS, ARP/wARP version
6.1 [65] was used to trace the initial protein model and
build side chains. Further refinement was carried out
using simulated annealing and conjugation gradient
minimization. When 97% of residues were built, the co-
factor PLP and the carbamylated lysine were placed, and
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Page 12 of 15positional and B-factor refinements were continued
resulting in an R and Rfree of 31.9 and 33.9%, respec-
tively. Water molecules were added using the water-
picking script in CNS, and further cycles of positional
and Biso refinements brought the R and Rfree to 20.7 and
25.7%, respectively. Since previous alanine racemase
structures have shown indications of subdomain move-
ment, we tried TLS refinement [43]. We used the TLS
motion determination server [66,67] to produce modified
PDB files and TLS input files for the structure partitioned
into either one, five or twenty TLS groups, then further
refined these models in Refmac5 version 5.5.0109 [44].
All models resulted in similar improvements in R and
Rfree so we used the simplest option, which treated all
protein atoms found in the asymmetric unit as a single
rigid body (one TLS group). PLP and Lys40 were
replaced with an LLP residue (PLP covalently bound to
lysine), and TLS refinement was completed using
Refmac5. The final model has an R and Rfree of 16.8 and
20.0%, respectively. Refinement statistics are listed in
Table 1. Structure factors and final atomic coordinates
for AlrSP have been deposited in the Protein Databank
(PDB ID: 3S46). B-factor values and correlation coeffi-
cients were calculated using the programs Baverage and
Overlapmap from the CCP4 suite [44].
Structural and sequence comparisons
The multiple structure-based sequence alignment and
structural superpositions of AlrSP with closely related
structures were performed using the protein structure
comparison service (SSM) at the European Bioinfor-
matics Institute (http://www.ebi.ac.uk/msd-srv/ssm) [68].
The PDB IDs of the structures used were: 1SFT (AlrGS),
1VFH (AlrSL), 3HA1 (AlrBA), and 3E5P (AlrEF). Table 3
lists the residues from these structures used in the
superpositions. Intermonomer interactions were ana-
lysed using the Protein Interfaces, Surfaces and Assem-
blies service (PISA) at the European Bioinformatics
Institute (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.
html) [69], and the Protein-Protein interface analysis
server (PROTORP) Server (http://www.bioinformatics.
sussex.ac.uk/protorp/ index.html) [70].
Figure preparation
Representations of molecules were prepared using the
programs PyMOL [71] and BKChem (http://bkchem.zir-
ael.org/index.html). The sequence alignment was visua-
lized using Jalview [72]. The electrostatic potential of
the AlrSP surface was calculated using the Adaptive
Poisson-Boltzmann Solver (APBS) [73] through PyMOL.
Default configurations were used for calculations. PQR
files for use with APBS were generated using the PDB
2PQR Server (http://kryptonite.nbcr.net/pdb2pqr/) [74]
and the Dundee PRODRG2 Server (http://davapc1.
bioch.dundee.ac.uk/prodrg/) [75].
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